Granules India has reported results for third quarter ended December 31, 2012.
The company, on the consolidated basis, has reported 27.28% fall in its net profit at Rs 5.81 crore for the quarter ended December 31, 2012 as compared to Rs 7.99 crore for the same quarter in the previous year. Total income of the company has increased by 5.12% at Rs 195.22 crore for quarter under review as compared to Rs 185.72 crore for the quarter ended December 31, 2011.
Granules is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1455.00 |
Dr. Reddys Lab | 5730.85 |
Cipla | 1459.75 |
Zydus Lifesciences | 1007.20 |
Lupin | 1564.60 |
View more.. |